# A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

> **NCT03589105** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 423 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab 300 mg
- **DRUG:** Ocrelizumab 600 mg

## Key facts

- **NCT ID:** NCT03589105
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-06
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589105, "A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03589105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*